GB2231263A - Use of neutral protease as activator for damaged neurocytes - Google Patents
Use of neutral protease as activator for damaged neurocytes Download PDFInfo
- Publication number
- GB2231263A GB2231263A GB8928811A GB8928811A GB2231263A GB 2231263 A GB2231263 A GB 2231263A GB 8928811 A GB8928811 A GB 8928811A GB 8928811 A GB8928811 A GB 8928811A GB 2231263 A GB2231263 A GB 2231263A
- Authority
- GB
- United Kingdom
- Prior art keywords
- activator
- neurocytes
- damaged
- neutral protease
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108091005507 Neutral proteases Proteins 0.000 title claims abstract description 26
- 102000035092 Neutral proteases Human genes 0.000 title claims abstract description 25
- 108090000145 Bacillolysin Proteins 0.000 title claims abstract description 24
- 239000012190 activator Substances 0.000 title claims abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 20
- 238000011282 treatment Methods 0.000 claims abstract description 20
- 201000010099 disease Diseases 0.000 claims abstract description 16
- 102000035195 Peptidases Human genes 0.000 claims abstract description 12
- 108091005804 Peptidases Proteins 0.000 claims abstract description 12
- 239000004365 Protease Substances 0.000 claims abstract description 11
- 244000005700 microbiome Species 0.000 claims abstract description 9
- 230000002265 prevention Effects 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- 108010059712 Pronase Proteins 0.000 claims abstract description 5
- 241000607720 Serratia Species 0.000 claims abstract description 4
- 241000187747 Streptomyces Species 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims abstract description 4
- 241000193830 Bacillus <bacterium> Species 0.000 claims abstract description 3
- 102000004190 Enzymes Human genes 0.000 claims description 10
- 108090000790 Enzymes Proteins 0.000 claims description 10
- 229940088598 enzyme Drugs 0.000 claims description 10
- -1 promelain Proteins 0.000 claims description 9
- 108010038132 serratiopeptidase Proteins 0.000 claims description 6
- 229940000634 serratiopeptidase Drugs 0.000 claims description 6
- 108090000631 Trypsin Proteins 0.000 claims description 4
- 102000004142 Trypsin Human genes 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000012588 trypsin Substances 0.000 claims description 4
- 235000019833 protease Nutrition 0.000 claims description 3
- 235000019419 proteases Nutrition 0.000 claims description 3
- CFYIUBWVKZQDOG-UHFFFAOYSA-N 4-[[2-[[2-[[1-(4-nitroanilino)-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-4-oxobutanoic acid Chemical compound C=1C=C([N+]([O-])=O)C=CC=1NC(=O)C(NC(=O)CNC(=O)CNC(=O)CCC(=O)O)CC1=CC=CC=C1 CFYIUBWVKZQDOG-UHFFFAOYSA-N 0.000 claims description 2
- 102000029816 Collagenase Human genes 0.000 claims description 2
- 108060005980 Collagenase Proteins 0.000 claims description 2
- 108010088842 Fibrinolysin Proteins 0.000 claims description 2
- 108010019160 Pancreatin Proteins 0.000 claims description 2
- 108090000526 Papain Proteins 0.000 claims description 2
- 108090001109 Thermolysin Proteins 0.000 claims description 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 2
- 229960002424 collagenase Drugs 0.000 claims description 2
- 229940001501 fibrinolysin Drugs 0.000 claims description 2
- 229940055695 pancreatin Drugs 0.000 claims description 2
- 229940055729 papain Drugs 0.000 claims description 2
- 235000019834 papain Nutrition 0.000 claims description 2
- 229960005356 urokinase Drugs 0.000 claims description 2
- 108010067372 Pancreatic elastase Proteins 0.000 claims 1
- 102000016387 Pancreatic elastase Human genes 0.000 claims 1
- 101100184487 Caenorhabditis elegans mnp-1 gene Proteins 0.000 description 24
- 208000009205 Tinnitus Diseases 0.000 description 15
- 231100000886 tinnitus Toxicity 0.000 description 15
- 239000003814 drug Substances 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 229960005205 prednisolone Drugs 0.000 description 12
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 12
- 210000001260 vocal cord Anatomy 0.000 description 12
- 206010011878 Deafness Diseases 0.000 description 11
- 231100000895 deafness Toxicity 0.000 description 11
- 208000016354 hearing loss disease Diseases 0.000 description 11
- 206010033799 Paralysis Diseases 0.000 description 10
- 206010011891 Deafness neurosensory Diseases 0.000 description 8
- 208000009966 Sensorineural Hearing Loss Diseases 0.000 description 8
- 229920001525 carrageenan Polymers 0.000 description 8
- 235000010418 carrageenan Nutrition 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 206010030113 Oedema Diseases 0.000 description 7
- 206010061373 Sudden Hearing Loss Diseases 0.000 description 7
- 230000001684 chronic effect Effects 0.000 description 7
- 210000002416 recurrent laryngeal nerve Anatomy 0.000 description 7
- 208000004929 Facial Paralysis Diseases 0.000 description 6
- 208000036826 VIIth nerve paralysis Diseases 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 230000000069 prophylactic effect Effects 0.000 description 6
- 239000003270 steroid hormone Substances 0.000 description 6
- 206010012289 Dementia Diseases 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 150000003431 steroids Chemical class 0.000 description 5
- 208000003265 stomatitis Diseases 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 206010013952 Dysphonia Diseases 0.000 description 4
- 208000010473 Hoarseness Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 230000001339 gustatory effect Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 208000037822 retinal angiopathy Diseases 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 229940126585 therapeutic drug Drugs 0.000 description 4
- 208000005232 Glossitis Diseases 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- 101150105005 MNP1 gene Proteins 0.000 description 3
- 101100184488 Schizosaccharomyces pombe (strain 972 / ATCC 24843) mrpl12 gene Proteins 0.000 description 3
- 101100316510 Schizosaccharomyces pombe (strain 972 / ATCC 24843) usb1 gene Proteins 0.000 description 3
- 241000187392 Streptomyces griseus Species 0.000 description 3
- 230000002146 bilateral effect Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000000256 facial nerve Anatomy 0.000 description 3
- 230000015654 memory Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000008786 sensory perception of smell Effects 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 102000004400 Aminopeptidases Human genes 0.000 description 2
- 108090000915 Aminopeptidases Proteins 0.000 description 2
- 102000005367 Carboxypeptidases Human genes 0.000 description 2
- 108010006303 Carboxypeptidases Proteins 0.000 description 2
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 201000007737 Retinal degeneration Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000035605 chemotaxis Effects 0.000 description 2
- 108010071720 chymoelastase Proteins 0.000 description 2
- 239000007931 coated granule Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 210000004709 eyebrow Anatomy 0.000 description 2
- 230000008921 facial expression Effects 0.000 description 2
- 230000033687 granuloma formation Effects 0.000 description 2
- 238000012074 hearing test Methods 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 210000004910 pleural fluid Anatomy 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229940043274 prophylactic drug Drugs 0.000 description 2
- 230000014860 sensory perception of taste Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 235000019605 sweet taste sensations Nutrition 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 206010002653 Anosmia Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000000477 Bilateral Hearing Loss Diseases 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000445129 Eremomyces bilateralis Species 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- FORGMRSGVSYZQR-YFKPBYRVSA-N L-leucinamide Chemical compound CC(C)C[C@H](N)C(N)=O FORGMRSGVSYZQR-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010036626 Presbyacusis Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- 241000187398 Streptomyces lividans Species 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 210000000860 cochlear nerve Anatomy 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000019604 hot taste sensations Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229940063199 kenalog Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000002859 lingual nerve Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 210000000196 olfactory nerve Anatomy 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 235000019643 salty taste Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 208000021510 thyroid gland disease Diseases 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Cardiology (AREA)
- Microbiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1114852A JPH02292226A (ja) | 1989-05-08 | 1989-05-08 | 障害された神経細胞賦活予防治療剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB8928811D0 GB8928811D0 (en) | 1990-02-28 |
| GB2231263A true GB2231263A (en) | 1990-11-14 |
Family
ID=14648320
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB8928811A Withdrawn GB2231263A (en) | 1989-05-08 | 1989-12-21 | Use of neutral protease as activator for damaged neurocytes |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JPH02292226A (enrdf_load_stackoverflow) |
| DE (2) | DE3941324A1 (enrdf_load_stackoverflow) |
| FR (1) | FR2646605B1 (enrdf_load_stackoverflow) |
| GB (1) | GB2231263A (enrdf_load_stackoverflow) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009007746A3 (en) * | 2007-07-06 | 2009-03-05 | Univ Sheffield | Treatment of sensorineural hearing loss |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007509982A (ja) | 2003-10-29 | 2007-04-19 | アルタス ファーマシューティカルズ インコーポレイテッド | 血漿コレシストキニン（ｃｃｋ）濃度を制御するための非膵臓プロテアーゼおよび痛みを処置するための非膵臓プロテアーゼ |
| CN109295041A (zh) * | 2018-10-10 | 2019-02-01 | 宁波希诺亚海洋生物科技有限公司 | 具有舍雷肽酶活性的多肽及其制备方法 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1064581A (en) * | 1964-04-06 | 1967-04-05 | Rorer Inc William H | Preparations containing an antitussive and an enzyme |
| GB1152697A (en) * | 1965-06-18 | 1969-05-21 | Denver Chemical Mfg Company | Improvements in or relating to Therapeutic Compositions |
| EP0057462A2 (en) * | 1981-02-03 | 1982-08-11 | Eisai Co., Ltd. | Elastase-containing composition permitting elastase to be absorbed in increased amount |
| GB2121685A (en) * | 1982-04-30 | 1984-01-04 | Kaken Pharma Co Ltd | Protease compositions for treating blood lipids abnormality and arteriosclerosis |
| EP0252004A1 (de) * | 1986-06-26 | 1988-01-07 | Ciba-Geigy Ag | Pharmazeutische Zusammensetzungen für die parenterale Applikation |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1955844A1 (de) * | 1969-11-06 | 1971-05-19 | Blendax Werke Schneider Co | Mittel zur Behandlung von Entzuendungen |
| US3860702A (en) * | 1972-07-11 | 1975-01-14 | Schuyler Dev Corp | Anti-inflammatory compositions |
| JPS5826822A (ja) * | 1981-08-10 | 1983-02-17 | Kaken Pharmaceut Co Ltd | 慢性腎炎治療剤 |
| WO1984002846A1 (en) * | 1983-01-21 | 1984-08-02 | Advanced Drug Tech | Enzyme ointment |
| JPS59225122A (ja) * | 1983-05-23 | 1984-12-18 | Kaken Pharmaceut Co Ltd | 悪液質治療改善剤 |
| JPS608227A (ja) * | 1983-06-28 | 1985-01-17 | Kaken Pharmaceut Co Ltd | 抗アレルギ−増強剤 |
| US4844897A (en) * | 1985-09-13 | 1989-07-04 | Hiroshi Maeda | Anti-tumor protease preparations |
| JPS62215533A (ja) * | 1986-03-17 | 1987-09-22 | Shigemi Fujisaki | 膠原病又は関節リウマチの予防治療剤 |
| JPS63295515A (ja) * | 1987-05-26 | 1988-12-01 | Kao Corp | 腸溶性抗血液凝固・血栓溶解製剤 |
| CH680285A5 (enrdf_load_stackoverflow) * | 1987-10-02 | 1992-07-31 | Ferag Ag |
-
1989
- 1989-05-08 JP JP1114852A patent/JPH02292226A/ja active Granted
- 1989-11-30 FR FR898915798A patent/FR2646605B1/fr not_active Expired - Lifetime
- 1989-12-14 DE DE3941324A patent/DE3941324A1/de active Granted
- 1989-12-14 DE DE3943649A patent/DE3943649C2/de not_active Expired - Fee Related
- 1989-12-21 GB GB8928811A patent/GB2231263A/en not_active Withdrawn
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1064581A (en) * | 1964-04-06 | 1967-04-05 | Rorer Inc William H | Preparations containing an antitussive and an enzyme |
| GB1152697A (en) * | 1965-06-18 | 1969-05-21 | Denver Chemical Mfg Company | Improvements in or relating to Therapeutic Compositions |
| EP0057462A2 (en) * | 1981-02-03 | 1982-08-11 | Eisai Co., Ltd. | Elastase-containing composition permitting elastase to be absorbed in increased amount |
| GB2121685A (en) * | 1982-04-30 | 1984-01-04 | Kaken Pharma Co Ltd | Protease compositions for treating blood lipids abnormality and arteriosclerosis |
| EP0252004A1 (de) * | 1986-06-26 | 1988-01-07 | Ciba-Geigy Ag | Pharmazeutische Zusammensetzungen für die parenterale Applikation |
Non-Patent Citations (1)
| Title |
|---|
| Martindale, The Extra Pharmacopoeia, 28th Edition,pp646-648, * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009007746A3 (en) * | 2007-07-06 | 2009-03-05 | Univ Sheffield | Treatment of sensorineural hearing loss |
Also Published As
| Publication number | Publication date |
|---|---|
| DE3941324C2 (enrdf_load_stackoverflow) | 1992-06-25 |
| JPH02292226A (ja) | 1990-12-03 |
| JPH0577655B2 (enrdf_load_stackoverflow) | 1993-10-27 |
| FR2646605A1 (fr) | 1990-11-09 |
| DE3941324A1 (de) | 1990-11-15 |
| DE3943649C2 (enrdf_load_stackoverflow) | 1992-10-29 |
| GB8928811D0 (en) | 1990-02-28 |
| FR2646605B1 (fr) | 1992-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW426520B (en) | Pharmaceutical compositions for the treatment of macular degeneration for preventing or improving exudative and non-exudative macular degeneration | |
| US4636489A (en) | Modified protease inhibitors, process for their preparation, and pharmaceutical compositions prepared therefrom | |
| JPS6028999A (ja) | 細胞増殖促進作用を有するたんぱく質、その組成物と製造方法 | |
| JPS62501002A (ja) | 高い眼圧の防止法、緑内障の処置及び高眼圧の処置 | |
| EP1480631B1 (en) | Methods of treating non-painful bladder disorders using alpha2-delta- subunit calcium channel modulators | |
| EP0140998B1 (en) | Ophthalmic preparations | |
| JP2008500304A (ja) | Ｄｐｐ−ｉｖ媒介症状の予防及び／又は治療用の薬剤製造のためのタンパク質加水分解物の使用 | |
| JP4278473B2 (ja) | ドライアイを治療又は予防する新規医薬組成物 | |
| GB2231263A (en) | Use of neutral protease as activator for damaged neurocytes | |
| SA03240363B1 (ar) | استخدام n-(-ميثوكسي-5-ميثيل بيرازين -2-يل)-2-(4- [4،3،1-اوكسا ديازول -2- يل)فينيل) بيريدين- 3- سلفوناميد في علاج السرطان | |
| EP0620737B1 (en) | Use of LACTOFERRIN iN the manufacture of a medicament for treating RHEUMATISM | |
| JP3183378B2 (ja) | ムチン産生促進剤 | |
| CA2003981C (en) | Pharmaceutical compositions and use thereof in the treatment of psoriasis | |
| JPH09249535A (ja) | 抗脱毛症剤 | |
| Herzberger et al. | Homeopathic treatment of infections of various origins: a prospective study | |
| WO2021001464A1 (en) | Combination therapy methods, compositions and kits | |
| JP3231821B2 (ja) | プロテインキナーゼｃ阻害剤 | |
| US20220257536A1 (en) | Ketamine and ketamine/nap for treatment of adnp syndrome and related neurological conditions | |
| JP2547325B2 (ja) | アレルギ−性疾患治療用外用剤 | |
| JP2982078B2 (ja) | イヌ上皮細胞成長因子、該イヌ上皮細胞成長因子を有効成分とする抗炎症剤又は化粧料、及び該イヌ上皮細胞成長因子ｃＥＧＦの製造方法 | |
| JPH01290631A (ja) | 血管内皮細胞増殖抑制剤 | |
| EP0679659A1 (en) | Cathepsin-l-specific inhibitor polypeptide | |
| JP2890170B2 (ja) | メタロエンドペプチダーゼｆ及びそれを有効成分とする薬剤 | |
| Bohn et al. | Treatment of ocular cicatricial pemphigoid with intravenous gammaglobulin. | |
| JPH04971B2 (enrdf_load_stackoverflow) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |